Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
Revenue
Evaxion Biotech A/S
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Revenue
$73k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Revenue
kr16.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
40%
|
CAGR 10-Years
38%
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Revenue
kr342.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
55%
|
CAGR 10-Years
48%
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Revenue
€329m
|
CAGR 3-Years
291%
|
CAGR 5-Years
83%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Revenue
kr7.1B
|
CAGR 3-Years
56%
|
CAGR 5-Years
70%
|
CAGR 10-Years
19%
|
Bioporto A/S
CSE:BIOPOR
|
Revenue
kr31m
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
6%
|
See Also
What is Evaxion Biotech A/S's Revenue?
Revenue
73k
USD
Based on the financial report for Dec 31, 2023, Evaxion Biotech A/S's Revenue amounts to 73k USD.